Corporate & Investor Presentation

Why invest? - driving long-term shareholder value Growth & Innovation Global leader in digital health for sleep and respiratory care • Long-term growth opportunities. 8,900+ patents and designs ~7-8% of revenue invested in R&D . 0000 Market Dynamics Underpenetrated markets in sleep and COPD Healthcare costs continue to increase · Focus on improving patient outcomes Value-based technology solutions Financial Results Historical revenue and profit growth • Recurring revenue • Operating excellence program Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 03/31/2022): 1-yr 26% 3-yr 139% 5-yr 255% 5 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed

View entire presentation